Oral small molecule GLP-1 receptor agonist
Lotiglipron 80 mg tablet once daily
LOTI_PO_80MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -2.33 (-7.63 to 3.90) | 0.49 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.29 (0.59 to 8.80) | 0.22 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.98 (1.77 to 8.93) | 0.23 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.15 (3.83 to 13.62) | 0.15 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.77 (2.52 to 14.09) | 0.26 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.83 (0.90 to 3.67) | 0.44 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.35 (1.51 to 7.99) | 0.23 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.91 (0.05 to 14.02) | 0.46 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.46 (0.01 to 17.65) | 0.56 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -2.27 (-8.01 to 4.46) | 0.20 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.33 (0.54 to 10.43) | 0.31 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.47 (1.37 to 8.99) | 0.34 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.30 (2.83 to 10.30) | 0.30 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.94 (1.74 to 14.92) | 0.44 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.36 (0.61 to 3.06) | 0.65 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.48 (0.89 to 6.84) | 0.42 |